Surgery for M1a Stage Lung Cancer with Pleural Metastasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and effectiveness of surgically removing the primary tumor in patients diagnosed with M1a stage lung cancer that has spread to the pleura. The study aims to determine if this surgical intervention can enhance overall survival and improve the quality of life for these patients. Participants will be closely monitored to evaluate outcomes related to their cancer treatment and recovery. The trial is observational, meaning it will collect data without assigning specific treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;
2. Aged 18-80 years (including critical values) when signing the informed consent form;
3. ECOG score 0 or 1;
4. No previous lung cancer surgery;
5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;
6. Occult pleural metastasis found during surgery;
7. First-time treatment and no radiotherapy or chemotherapy.

Exclusion Criteria:

1. The lesion cannot be completely removed surgically;
2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;
3. Patients who have undergone lung cancer surgery before;
4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.

Where it's running

• Fudan University Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Fangqiu Fu, MD
• Email: fufangqiu12@163.com
• Phone: 021-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M14D1 plus atezolizumab vs standard therapy in first-line extensive-stage small cell lung cancer

  A first-line treatment for adults with extensive-stage small cell lung cancer tests whether adding BL-M14D1 to atezolizumab and standard chemotherapy helps more than standard care.

  Recruiting at 7 sites Phase 3 SystImmune Inc. · Springdale, Arkansas and 61 other locations · NCT07625644

• Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer

  This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.

  Recruiting RenJi Hospital · Shanghai · NCT07026110

• Investigating blood clotting changes in meningioma surgery

  This study looks at how blood clotting changes in patients with meningiomas during surgery to see if it affects their risk of blood clots compared to those having surgery for gliomas.

  Recruiting University Hospital Tuebingen · Tübingen, Baden-Wurttemberg · NCT06709833

• Combining TIL Therapy and Pembrolizumab for Advanced Lung Cancer

  This study is testing a new treatment that combines a special type of immune cells from patients' tumors with an existing cancer drug to see if it helps people with advanced lung cancer feel better and live longer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT06538012

• Treatment of advanced lung cancer using KB707

  This study is testing a new treatment called KB707 to see if it can help adults with advanced lung cancer by boosting their immune response, especially for those who haven't had success with standard therapies.

  Recruiting at 10 sites Phase 1/2 Krystal Biotech, Inc. · Dothan, Alabama and 13 other locations · NCT06228326

• Integrative platform for personalized lung cancer care using AI

  This study is trying to create a smart tool that helps doctors predict how well immunotherapy will work for people with non-small cell lung cancer, so they can make better treatment choices.

  Recruiting at 4 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Chicago, Illinois and 3 other locations · NCT05537922

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.